QOP
EDIT icon

Quinn Opportunity Partners’s Editas Medicine EDIT Stock Holding History

Quinn Opportunity Partners’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Buy
+40,000
New +$117K 0.01% 339

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Quinn Opportunity Partners's EDIT Position: Q2 2026 in Review

Quinn Opportunity Partners opened a new position in Editas Medicine (EDIT) in Q2 2026: 40,000 shares worth $130K. The stake represents 0.01% of the portfolio and ranks #339 among its holdings.

214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Quinn Opportunity Partners held 40,000 shares of Editas Medicine worth $130K as of Q2 2026.
  • Editas Medicine was a new Quinn Opportunity Partners position in Q2 2026.
  • Editas Medicine made up 0.01% of Quinn Opportunity Partners's portfolio in Q2 2026, its #339 holding.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Quinn Opportunity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.